Biocryst pharmaceuticals inc (BCRX)
Balance Sheet / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Dec'10
Assets
Cash and cash equivalents

101,873

114,172

29,903

30,760

34,804

26,731

52,584

27,104

43,767

50,282

117,776

39,696

75,158

22,104

35,387

8,661

12,902

28,899

46,627

76,781

48,367

54,540

121,157

121,519

13,584

21,164

26,050

19,767

14,805

20,891

23,959

21,924

27,661

16,444

22,441

17,008

13,622

Restricted cash

1,559

1,551

1,547

4,629

2,394

1,544

1,506

7,625

4,599

3,286

3,122

5,357

2,798

1,546

1,506

4,426

1,965

1,612

1,622

1,569

2,637

150

150

150

150

151

150

2,129

616

308

300

2,230

955

625

625

1,416

625

Investments

11,185

22,054

38,532

61,387

72,753

77,736

67,737

53,636

47,540

64,115

43,848

40,977

23,524

32,546

17,434

27,079

22,914

22,664

23,700

17,584

19,160

18,232

5,977

10,589

17,807

16,891

16,541

9,358

13,462

14,708

17,062

12,958

15,617

25,274

21,558

40,583

40,323

Receivables from collaborations

5,642

22,146

3,598

3,602

5,002

4,293

3,394

2,342

5,694

6,117

8,985

3,325

9,564

8,768

5,968

2,234

-

6,243

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest reserve

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,742

1,742

1,742

1,742

3,000

0

Inventory

-

-

1,776

1,000

600

1,649

821

221

7

-

0

1,305

655

500

2,232

1,949

1,949

1,612

0

1,308

1,210

683

-

-

-

-

-

-

-

-

263

263

263

263

898

898

898

Receivables

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,238

897

3,280

-

2,369

1,024

4,325

4,562

3,768

5,084

5,852

5,831

11,634

15,961

30,227

Prepaid expenses and other current assets

5,249

4,422

3,447

2,341

2,087

2,399

2,445

1,729

2,397

1,381

1,421

1,524

1,721

1,438

2,007

1,674

3,221

2,674

4,970

5,449

4,322

6,172

4,546

5,020

835

1,725

1,656

1,179

1,781

1,097

826

344

407

378

795

260

1,005

Deferred collaboration expense

-

-

-

-

9

-

8

12

152

210

218

79

82

85

98

89

90

90

88

101

76

76

76

75

75

75

73

73

418

412

404

519

452

2,301

753

751

719

Total current assets

125,508

164,345

78,803

103,719

117,649

114,352

128,495

92,669

104,156

125,391

175,370

92,263

113,502

66,987

64,632

46,112

50,425

63,794

84,502

107,088

81,366

89,343

135,144

138,250

35,731

42,121

46,839

33,530

35,407

41,978

46,582

45,064

52,949

52,858

60,446

79,877

87,419

Investments

-

-

-

741

11,655

22,376

29,157

33,744

41,599

41,295

4,539

9,603

3,803

8,926

14,371

24,154

41,134

47,683

47,787

36,059

41,116

41,116

302

602

2,679

2,582

680

0

-

1,151

2,513

16,351

13,067

15,382

16,416

12,984

11,771

Property and equipment, net

7,270

7,347

7,452

7,551

7,644

9,135

9,236

9,390

9,395

9,546

9,613

9,602

9,753

9,922

10,095

10,112

8,362

5,149

1,146

1,047

727

207

210

216

260

306

359

425

486

583

751

882

999

1,098

1,353

1,537

1,929

Deferred collaboration expense

-

-

-

-

-

-

-

-

-

-

15

170

184

199

214

229

246

265

282

288

163

177

192

207

222

237

252

266

4,932

5,033

5,134

5,235

5,336

5,437

7,139

7,319

8,328

Other assets

3,811

3,590

4,245

4,333

5,390

978

1,420

841

222

2,027

1,955

1,871

2,271

3,813

2,190

1,610

2,714

5,468

5,239

5,699

6,495

6,031

1,277

2,700

4,495

3,620

5,075

5,695

6,074

8,694

9,114

8,704

7,734

7,433

7,157

6,695

0

Total assets

136,589

175,282

90,500

116,344

142,338

146,841

168,308

136,644

155,372

178,259

191,492

113,509

129,513

89,847

91,502

82,217

102,881

122,359

138,956

150,181

129,867

136,874

137,125

141,975

43,387

48,866

53,205

39,916

46,899

57,439

64,094

76,236

80,085

82,208

92,511

108,412

109,447

Liabilities and Stockholders’ Equity
Accounts payable

10,061

13,988

10,084

8,298

6,935

7,769

7,911

4,122

3,588

6,337

4,603

1,844

5,433

4,269

2,760

5,051

7,691

9,307

3,782

3,822

5,307

2,849

2,266

2,360

1,352

4,174

1,241

989

1,073

3,974

2,293

3,328

2,062

2,497

3,583

5,012

8,201

Accrued expenses

20,192

21,365

24,954

19,343

16,547

15,891

15,120

19,409

15,624

12,699

11,871

12,329

11,335

10,836

10,782

11,783

17,328

16,237

23,027

19,001

12,291

11,329

11,252

7,309

6,312

5,742

7,668

5,773

5,647

9,860

8,035

8,206

9,253

12,616

12,030

12,309

17,302

Interest payable

16,381

14,904

13,423

14,745

13,392

11,848

10,427

14,832

13,465

12,095

10,705

11,587

10,291

8,990

7,563

9,203

7,974

6,746

5,517

4,450

7,241

6,029

4,824

3,786

4,552

3,867

2,734

3,658

3,068

1,998

928

3,500

2,450

1,400

350

1,318

0

Deferred collaboration revenue

1,067

2,120

221

221

221

221

200

300

7,300

8,484

8,686

1,717

1,869

2,022

2,282

2,134

-

2,163

-

-

-

-

1,481

1,482

1,473

-

1,539

1,538

1,536

1,392

1,308

4,072

2,400

9,786

3,370

3,321

2,497

Lease financing obligation

1,301

1,377

-

-

-

47

66

78

76

75

73

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Senior credit facility

14,026

9,020

4,036

-

-

4,580

1,621

6,530

6,497

6,464

4,727

2,997

1,276

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-recourse notes payable

29,671

29,561

29,451

29,341

29,231

29,121

29,012

28,902

28,792

28,682

28,572

28,463

28,353

28,243

28,133

28,023

27,914

27,804

-

-

-

30,000

30,000

30,000

-

0

-

-

-

-

-

-

-

-

-

-

-

Total current liabilities

92,699

92,335

82,169

71,948

66,326

69,477

64,357

74,173

75,342

74,836

69,237

58,937

58,557

54,360

51,520

56,194

63,070

62,257

64,444

63,772

61,862

57,293

49,823

44,937

13,689

15,256

13,182

11,958

11,324

17,224

12,564

19,106

16,165

26,299

19,333

21,960

28,000

Deferred collaboration revenue

-

-

-

-

-

-

-

-

-

-

296

7,592

7,888

8,184

8,480

8,776

9,194

9,674

10,122

9,959

3,256

3,552

3,848

4,144

4,440

4,736

5,032

5,327

5,624

5,920

6,215

6,512

6,808

7,103

14,072

14,695

15,944

Deferred rent

-

-

-

-

-

54

81

107

131

155

178

201

223

244

265

297

313

329

345

361

378

394

-

-

-

-

-

-

-

-

-

-

-

-

138

151

-

Lease financing obligation

3,729

3,406

3,543

3,742

3,889

2,703

2,704

2,711

2,731

2,751

2,770

2,704

2,704

2,704

2,675

2,589

2,506

2,375

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-recourse notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

30,000

30,000

30,000

-

0

0

30,000

30,000

30,000

30,000

30,000

30,000

30,000

30,000

30,000

30,000

30,000

30,000

0

Foreign currency derivative

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,904

974

-

-

-

-

-

-

-

2,805

981

-

1,581

1,678

2,791

4,749

5,531

4,959

3,962

4,000

2,926

2,340

0

Senior credit facility

36,513

41,289

46,041

49,847

49,616

25,372

28,293

13,469

15,114

16,750

18,379

19,999

21,611

22,777

22,665

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Commitments and contingencies

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

-

Stockholders’ equity:
Preferred stock, $0.001 par value; shares authorized - 5,000; no shares issued and outstanding

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Common stock, $0.01 par value: shares authorized - 200,000; shares issued and outstanding – 154,192 in 2020 and 154,082 in 2019

1,542

1,541

1,104

1,104

1,103

1,101

1,096

989

987

984

984

804

804

738

738

737

737

734

733

732

725

720

719

717

601

591

591

542

514

509

509

501

492

457

452

451

450

Additional paid-in capital

880,319

877,300

795,589

790,076

784,278

780,400

776,724

720,587

718,037

714,869

711,965

620,453

618,009

566,913

564,791

562,634

560,762

558,113

556,095

553,610

546,698

542,943

538,959

536,864

426,520

420,988

420,097

399,684

393,738

391,611

390,783

386,966

382,181

367,829

365,868

364,593

361,520

Accumulated other comprehensive income

14

39

60

41

-89

-297

-410

-452

-476

-243

-17

-15

-3

-12

22

46

48

-206

-1

-92

10

-130

2

3

2

4

2

6

15

27

40

40

49

40

50

92

105

Accumulated deficit

-878,227

-840,628

-838,006

-800,414

-762,785

-731,969

-704,537

-674,940

-656,494

-631,843

-612,300

-597,166

-580,280

-566,061

-561,558

-550,030

-533,749

-510,917

-492,782

-478,161

-483,062

-467,898

-456,226

-447,495

-432,846

-422,709

-417,280

-409,279

-397,107

-392,601

-381,548

-371,848

-359,572

-353,520

-340,328

-325,870

-296,572

Total stockholders’ equity

3,648

38,252

-41,253

-9,193

22,507

49,235

72,873

46,184

62,054

83,767

100,632

24,076

38,530

1,578

3,993

13,387

27,798

47,724

64,045

76,089

64,371

75,635

83,454

90,089

-5,723

-1,126

3,410

-9,047

-2,840

-454

9,784

15,659

23,150

14,806

26,042

39,266

65,503

Total liabilities and stockholders’ equity

136,589

175,282

90,500

116,344

142,338

146,841

168,308

136,644

155,372

178,259

191,492

113,509

129,513

89,847

91,502

82,217

102,881

122,359

138,956

150,181

129,867

136,874

137,125

141,975

43,387

48,866

53,205

39,916

46,899

57,439

64,094

76,236

80,085

82,208

92,511

108,412

109,447